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Abstract
The firefly bioluminescence reaction has been exploited for in vivo optical imaging  
in life sciences. To develop highly sensitive bioluminescence imaging technology, 
many researchers have synthesized luciferin analogs and luciferase mutants. This 
chapter first discusses synthetic luciferin analogs and their structure–activity rela-
tionships at the luminescence wavelength of the firefly bioluminescence reaction. We 
then discuss the development of luciferin analogs that produce near-infrared (NIR) 
light. Since NIR light is highly permeable for biological tissues, NIR luciferin analogs 
might sensitively detect signals from deep biological tissues such as the brain and 
lungs. Finally, we introduce two NIR luciferin analogs (TokeOni and seMpai) and 
a newly developed bioluminescence imaging system (AkaBLI). TokeOni can detect 
single-cell signals in mouse tissue and luminescence signals from marmoset brain, 
whereas seMpai can detect breast cancer micro-metastasis. Both reagents are valid for 
in vivo bioluminescence imaging with high sensitivity.
Keywords: Firefly bioluminescence, Bioluminescence imaging, Structure–activity 
relationships, Multicolor, Near-infrared light
1. Introduction
In Japan, watching the light of fireflies has been a summer tradition for over one 
thousand years. Modern fireflies are known to glow yellow-green, but in ancient 
times they emitted a dark green luminescence, as confirmed by recent molecular 
biology techniques [1]. The detailed mechanism of firefly bioluminescence is 
described in previous chapters. This chapter focuses on synthetic substrates of 
firefly luciferase, which are employed in firefly bioluminescence imaging (BLI).
In recent biological research, BLI technology has observed biological events in 
vivo [2–8]. For example, in cancer research, BLI has been applied to real-time moni-
toring of gene expression, cell numbers, and other biological events in transgenic 
mouse models [9–16]. Our group has developed firefly substrate analogs for use in 
these research fields.
The firefly bioluminescence reaction proceeds via the oxidation of d-luciferin 
(1, LH2, Figure 1) catalyzed by firefly luciferase (Fluc) in the presence of adenosine 
triphosphate (ATP), Mg2+ and O2 by a two-step reaction. In the first step, LH2 is 
adenylated with ATP, and is then oxidized by O2, forming excited-state oxyluciferin 
that relaxes to the ground state with yellow-green light emission (λmax = 560 nm) 
[17–19]. However, yellow-green light is not able to easily penetrate biological tissues 
[20], and is useful only for imaging shallow tissues such as subcutaneous tissues. To 
detect signals from deep tissues such as brain and lung [21], near-infrared (NIR) 
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light should be used, as it is highly permeable to biological tissues [20] and is suit-
able for in vivo deep tissue imaging [21]. Recently, many synthetic luciferin analogs 
have been reported. Our group has synthesized various luciferin analogs and com-
pared them with 1. By studying the structure–activity relationships of these analogs 
and Photinus pyralis (Ppy) luciferase, we have developed luciferin analogs that 
produce wide-spectrum light (from blue to red), along with NIR luciferin analogs 
(AkaLumine, TokeOni, seMpai) for BLI. Our different analogs are described in this 
chapter.
2. Luciferin analogs of firefly luciferase
Many researchers have synthesized luciferin analogs, and different substrates 
reacted with luciferases exhibit different luminescence activities [22–24]. Most 
luciferin analogs are formed by modifying the benzothiazole moiety of 1. Analogs 
of 1 were first synthesized by White et al. in 1966. They showed that aminoluciferin 
(2, Figure 1), in which the hydroxyl group of benzothiazole is replaced with an 
amino group, can function as a substrate of Fluc and emit red bioluminescence [25].
2.1 Development of luciferin analogs based on LH2
As mentioned above, many luciferin analogs are prepared by modifying the 
benzothiazole moiety of 1 [22–24]. For instance, N-cycloaminoluciferins  
(2a–f, Figure 2A) are prepared by cyclizing the NH2 of 2. These analogs were 
reported by two independent groups, who synthesized them by different routes 
[26, 27] (Figure 2B–C). When reacted with Fluc, 2a–f show longer wavelengths 
than 1, probably reflecting the electron donation effect of cycloamine substitutes. 
Comparing the bioluminescence activities and emission wavelengths of analogs 
2e and 2f on Fluc and Fluc mutant luciferase R218K, it was found that 2e/Fluc 
and 2f/R218K produced light at 604 and 614 nm, respectively, whereas 2e/R218K 
and 2f/Fluc produced no light [26]. The interaction between the active site of 
luciferase and the substrate is very critical, indicating that the structures of both 
reactants play essential controlling roles in luminescence activity.
Miller et al. synthesized CycLuc1 (7a, Figure 3) by fusing N-cycloalikylation of 
2 with benzothiazole [28]. Analog 7a exhibited a longer luminescence wavelength 
on Fluc (599 nm) than 1 on Fluc, and was emitted more intensely than 1 in a 
Photuris pennsylvanica firefly luciferase mutant (Ultra-Glo). The BLI of 7a detects 
the signals from deep organs such as brains and lungs [21, 29]. Li et al. synthesized 
CybLuc (7b, Figure 3) by substituting the hydroxy group of 2 with a cycloamino 
group. Analog 7b produced light at 603 nm and its BLI detected the signals from 
mouse brain [30].
Iwano et al. developed luciferin analogs 8a–g (Figure 4A) by substituting the 
benzothiazole moiety of 1 with a simple benzene ring and extended π-conjugations 
[31]. Olefins were extended by the Wittig reaction from 10c–d and 12e–f as starting 
Figure 1. 
Structures of d-luciferin (1, LH2) and aminoluciferin (2).
3
Near-Infrared Luciferin Analogs for In Vivo Optical Imaging
DOI: http://dx.doi.org/10.5772/intechopen.96760
materials. In this synthesis, hydrolysis was stepwise followed by condensation 
with d-Cys(STrt)-OMe, thiazoline cyclization, and methyl ester deprotection 
(Figure 4B). The obtained analogs 8a–f produced luminescent colors over a wide 
range (blue to red) [31]. Among these, AkaLumine (8e), which produces light at 
675 nm, is a leading compound for NIR luciferin analogs, as described in Section 
2.2. Later, analog 8e was used as a reagent for BLI. In the same paper, 3-hydroxyl 
analog 8g (Figure 4A) was also synthesized, but this analog produced no light 
[31]. Therefore, the position of the OH substituent is critical in the firefly  
bioluminescence reaction.
In contrast, the thiazoline site is rarely modified. Conley et al. synthesized 
a seleno-aminoluciferin analog 13a (Figure 5A) in which the S of the thia-
zoline ring of 2 was replaced with Se [32], and Ioka et al. synthesized O- or 
C- substituted analogs 13b–c (Figure 5A) [33]. Analog 13a, which produced 
light at 600 nm, was synthesized by the cyclization reaction of selenocysteine 
(Figure 5B) [32]. Analog 13b was obtained by synthesizing an amide 16b syn-
thesizing an amide from d-serine, cyclizing it with diethylaminosulfur trifluo-
ride (DAST), and hydrolyzing it with Amano lipase (Figure 5C). Analog 13c 
was prepared by coupling with bromothiazole 19 and pyrrolidione carboxylate 
21 to form glutamate-linked benzothiazole 16c, and cyclizing 16c with trifluo-
roacetic acid (TFA) (Figure 5D). Interestingly, 13c produces light at 547 nm, 
whereas 13b is non-bioluminescence [33] but shows chemiluminescent ability. 
This result indicates that the thiazoline of 1 is an essential moiety for recogniz-
ing the activity site in luciferase.
Figure 2. 
Structures and synthetic routes of luciferin analogs 2a–f. (A) N-cycloaminoluciferin analogs 2a–f, (B) the 
synthetic route reported by Miller et al. [28], and (C) the synthetic route reported by Hirano et al. [29].
Figure 3. 
Structures of CycLuc1 (7a) and CybLuc (7b).
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2.2 Structure–activity relationships for developing NIR luciferin analogs
Based on these structure–activity relationships, additional luciferin analogs 
have been designed and synthesized for NIR light production. For example, 
Anderson et al. synthesized iLH2 (22, Figure 6) by inserting an olefin into the 
structure of 1. Analog 22 produced NIR light at 706 nm [34]. However, the lucifer-
ase used at that time was a mutant (S284T), and the luminescence wavelength on 
Fluc was 670 nm. The same authors developed an in vivo dual-imaging technique 
that combines 1 and 22 with two different luciferases. This system can potentially 
observe new biological events by tracking two processes simultaneously [35]. 
Hall et al. synthesized NH2–NpLH2 (23, Figure 6) by extended conjugation of 
2. Analog 23 produced no light with Fluc, but its luminescence wavelength was 
extended to 743 nm by reaction with CBR2, a mutant luciferase of click beetles 
(Pyrophorus plagiophthalamus) [36]. All of these studies achieved long-wavelength 
emissions from mutant luciferases, but their luminescence activity is much lower 
than that of combinations of 1 and wild type Ppy luciferase.
Figure 4. 
Structures of 8a–g (A) and their synthetic routes 8a–f (B).
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Meanwhile, Maki’s group has developed a number of analogs based on the struc-
ture of 8e, which are expected to produce NIR light. Miura et al. formed a mother 
skeleton by a coupling reaction, and thus synthesized biphenyl analogs 24a–c 
(Figure 7 and 8A) [37]. Analog 24a produced light at 675 nm, but the luminescence 
intensity was weak. Although its conjugation was more extended than in 8e, the 
luminescence wavelength of 24a did not change as that of 8e (675 nm). This result 
suggests that the biphenyl moiety rotates and reduces the fluorescent intensity.
Kiyama et al. synthesized cyclic amino analogs of 8e (25a–d, Figure 7) [38] 
from 4-fluorobenzaldehyde 32 as the starting material. They replaced the F group 
with various secondary amines, and conducted the Horner–Wadsworth–Emmons 
Figure 5. 
Structures of 13a–c (A) and their synthetic routes 13a (B), 13b (C) and 13c (D).
Figure 6. 
Structures of NIR luciferin analogs iLH2 (22) and NH2-NpLH2 (23).
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reaction, condensation and cyclization to obtain the final compounds 25a–d 
(Figure 8B). Despite containing an electron-donating amino group, 25a–d pro-
duced luminescence at almost the same wavelengths (656–667 nm) as 8e (668 nm). 
However, the luminescence intensity of 25a was approximately four times stronger 
than that of 8e. The fluorescence quantum yields of 8e and these cyclic amino 
analogs 25a–d were almost identical, suggesting that the luminescence intensity 
largely depends on the reactivity with luciferase.
The luminescent wavelength can be lengthened not only by extending the 
π-conjugations and introducing an electron donate substituent, but also by intro-
ducing an allyl group. Kitada et al. synthesized allyl analogs 26a–b (Figure 7) by 
introducing allyl groups into 8c, 8e and naphthol analogs 27a–d (Figure 7). The 
analogs were introduced by two routes: Pd-catalyzed Stille coupling (Figure 8C) 
and Claisen rearrangement (Figure 8D) [39]. Although these analogs delivered 
very low luminescence intensities, their wavelength shift was long (approxi-
mately 15–35 nm). As the allyl group itself does not affect the π-conjugations of 
the substrate structure, it was considered that induce fitting was occurred at the 
luciferase active site and stabilized the substrate metabolite to lower energy state 
conformation. To develop a long-wavelength, Kitada et al. synthesized NIR analog 
(28 in Figure 7) by introduced both an electron-donating NMe2 and an allyl group. 
When reacted with Fluc, 28 produced NIR light at a sufficiently long-wavelength 
(705 nm), but the luminescence intensity was only 1.3% of that of 8e. Although the 
allyl group extends the luminescent wavelength, it greatly reduces the luminescence 
intensity, which is a major disadvantage.
The aromatic ring site has also been targeted in the development of potential 
NIR emitters. Saito et al. synthesized three analogs 29a–c (Figure 7) in which the 
Figure 7. 
Structures of NIR luciferin analogs 24–29.
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aromatic ring of 8e was replaced with an N-heteroaromatic ring [40]. Interestingly, 
the luminescence wavelengths of three analogs depended on the positions and 
numbers of their N atoms; 29a produced red light at 645 nm, seMpai (29b) produced 
NIR light at 675 nm, and 29c produced orange light at 625 nm. This result highlights 
the importance of interactions between the luciferase active site and the N atoms 
of the heterocycle. Although the luminescence wavelength of all three analogs were 
shorter than 700 nm, the wavelength was changed with a single atom, suggesting that 
interaction with the luciferase active site is an important part of molecular design.
3.  Solubility enhancement of TokeOni and seMpai (29b) for sensitive  
in vivo imaging
As mentioned in the previous section, our research group has developed 
multicolor luciferin analogs for in vivo imaging. The luminescence activities of 
AkaLumine (8e) and seMpai (29b) are potentially suitable for BLI. Therefore, 
the usefulness of these analogs as reagents for in vivo BLI was evaluated in further 
animal experiments.
Figure 8. 
Synthetic routes of NIR luciferin analogs 24a–c (A), 25a–d (B), 26a–b (C) and 27a–d (D).
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3.1 Development of AkaBLI (TokeOni and AkaLuc)
Prior to administering the reagent into the animal models, we increased the aqueous 
solubility of 8e (which is inherently low) and developed an HCl salt of 8e, AkaLumine-
HCl (Tokeoni) [21]. In ultrapure water, the solubility of TokeOni was 40 mM, 
approximately 20 times higher than that of 8e (2 mM). Therefore, TokeOni enable 
to administered to experimental animals with a smaller solution volume and higher 
concentration than 8e. TokeOni/Fluc BLI was performed with significantly higher 
sensitivity than LH2/Fluc and CycLuc1/Fluc in the lungs [21] and brain [41] of mice. 
However, as the in vitro luminescence intensity of TokeOni/Fluc was lower than that of 
LH2/Fluc, it must be improved before imaging large animals such as marmosets.
Accordingly, Iwano et al. developed a mutant luciferase Akaluc specialized for 
TokeOni. They developed the artificial bioluminescence system AkaBLI, which 
combines TokeOni with Akaluc [42] (a mutation of 28 amino acid residues on 
Ppy luciferase). The AkaBLI luminescence intensity was approximately 10-fold 
higher in cells (in vitro), 52-fold higher in mouse lungs (in vivo), and 1400-fold 
higher in mouse brain tissue (in vivo) than LH2/Fluc luminescence intensity. In 
addition, AkaBLI detected single-cell signals from mouse lung and to quantified 
1–10 cells. For large animal imaging, the authors inserted the Akaluc gene into an 
adeno-associated virus (AAV) vector, and introduced the recombinant AVV into 
the striatal neurons of marmosets. AkaBLI achieved video-rate real-time imaging of 
marmoset brains.
3.2 BLI with seMpai
seMpai (29b) was developed to improve two weak points in TokeOni: neutral pH 
and disturbance by hepatic background signals. As TokeOni is acidic [43], it may cause 
acidosis when injected; moreover, TokeOni detects the hepatic background signals, 
which are not detected by LH2 [43, 44]. Due to the effect of N atom, seMpai was suf-
ficiently soluble for administration to experimental animals and 69 mM was dissolved 
in phosphate buffered saline (pH 7.4) [40]. In Fluc-expressing lung cancer model 
mice, the sensitivities of seMpai and TokeOni were not significantly different [40], 
but seMpai detected no hepatic background signals and seMpai BLI detected breast 
cancer micro-metastasis [43]. When repeated with TokeOni and LH2, this experiment 
was unsuccessful. Although seMpai/Fluc was less sensitive than AkaBLI for single-cell 
imaging, its imaging sensitivity could be improved mutant luciferases such as Akaluc.
Fukuchi et al. monitored the expression of brain-derived neurotrophic factor 
(BDNF) in Bdnf-luc transgenic mice with LH2, TokeOni, and seMpai [45]. TokeOni 
achieved the most sensitive BLI, and seMpai and LH2 were comparable. The result 
probably reflects the different abilities of the compounds to penetrate the blood–
brain-barrier. This result also indicates the necessary of evaluating the imaging 
reagent in terms of both its luminescence activity and pharmacokinetics.
Additionally, biocompatibility such as cytotoxicity of TokeOni and seMpai has 
not been reported yet. No acute toxicity or adverse side effects were observed in 
mice when these compounds were administered at a concentration of 33 mM [40], 
however, preliminary experiments are recommended when using new analogs, not 
limited to TokeOni and seMpai.
4. Conclusion
By investigating the structure–activity relationship of luciferin analogs, 
researchers have developed various methods for tuning the luminescence 
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wavelengths of these analogs. However, the intensity of the luminescence is poorly 
controlled. If the luminescence intensity and structure–activity relationships could 
be to associated by a predictable law, we could synthesize new luciferin analogs 
with high luminescence intensity, and further develop an imaging technology with 
greater usefulness than conventional technologies.
For a practical imaging technology, both the luminescent substrate/enzyme 
activity and the pharmacokinetics are very important. Improving the various prop-
erties of the substrates and enzymes will enhance the sensitivity of bioluminescence 
imaging.
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